Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

BACKGROUND: Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early SIT intro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Abu-Sbeih, Hamzah, Ali, Faisal S., Wang, Xuemei, Mallepally, Niharika, Chen, Ellie, Altan, Mehmet, Bresalier, Robert S., Charabaty, Aline, Dadu, Ramona, Jazaeri, Amir, Lashner, Bret, Wang, Yinghong
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444537/
https://ncbi.nlm.nih.gov/pubmed/30940209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0577-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi